5 papers about lung cancer suggested by Stephen Liu

Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers on X:

First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world study

Authors: L. Moliner et al.

Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III non-small cell lung cancer according to epidermal growth factor receptor and anaplastic lymphoma kinase status: Korean Cancer Study Group LU-22-18

Authors: Dae-Ho Choi et al.

Entrectinib-Induced Myocarditis and Acute Heart Failure responding to steroid treatment: a case report

Authors: Mehraab N. Majeed, Subramanian Venkatesan, Dionysis Papadatos-Pastos, Tanya Ahmad, Martin Forster, Polyvios Demetriades, Daniel Johnathan Hughes, Sarah Benafif, Siow-Ming Lee

Real-world outcomes of pralsetinib in RET fusion-positive non-small cell lung cancer

Authors: Francesca Lucibello et al.

S1701, A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma

Authors: Anne S. Tsao et al.

Follow Stephen Liu on X for more such content.

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.